Sichuan Biokin’s Multi-Specific Antibody GNC-077 Gets NMPA Nod for Advanced Solid Tumor Clinical Trial

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to advance its drug candidate, GNC-077, into clinical trials for the treatment of advanced solid tumors. GNC-077 is a multi-specific antibody developed on the GNC platform, a proprietary research and development arm of Biokin focused on multi-specific antibody therapies. This innovative treatment combines antibody domains that target T cell CD3 and T cell immune checkpoints with domains that target tumor antigens. GNC-077 is designed to effectively activate, differentiate, and proliferate T cells, enabling them to specifically target and kill tumor cells that express the relevant antigens. Preliminary in vivo studies have demonstrated the drug candidate’s potent anti-tumor effects across a range of solid tumor types.- Flcube.com